0
0
Glasgow, UK – A new study published in Diabetes, Obesity and Metabolism has shed light on the potential mechanisms behind behavioral side effects observed in some individuals using popular weight loss medications known as glucagon-like peptide 1 receptor agonists (GLP1RAs).
GLP1RAs, like Ozempic and Wegovy, have gained significant attention for their effectiveness in aiding weight loss and managing type 2 diabetes. However, some users have reported experiencing side effects such as anxiety, mood swings, and increased risk-taking behavior.
The study, conducted by researchers at the University of Glasgow, analyzed genetic variations in the GLP1R gene across individuals of diverse ancestries. While these variations were linked to cardiometabolic traits like body mass index and blood pressure, the researchers found that the genetic factors influencing these traits were distinct from those associated with behavioral changes.
“Our findings suggest that any observed behavioral changes with GLP1RA are likely not acting directly through GLP1R,” said lead author Rona J. Strawbridge, Ph.D. “Exactly how these indirect effects are occurring is currently unclear.”
The study emphasizes the need for further research to understand the precise mechanisms behind these potential side effects. While GLP1RAs have shown significant promise in combating obesity and related health issues, it’s crucial to carefully monitor individuals for any unexpected behavioral changes and to continue investigating the underlying causes.
Disclaimer: This news article is for informational purposes only and should not be considered medical advice.
